Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 204.27B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 12.59 |
| Forward PE | 10.53 |
| Dividend | 2.91 (3.55%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 3,399 |
| Average Volume | 4,283 |
| Open | 81.10 |
| Previous Close | 81.90 |
| Day's Range | 81.10 - 85.10 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.32 |
| RSI | 72.20 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Retirement: 2 Healthcare Giants To Buy At Discounted Prices
Merck and Elevance Health stocks are top dividend growth picks with solid yields and attractive valuations. Click here to learn more about MRK and ELV.
The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock
V benefits from rising cross-border volumes and strong digital payments momentum as analysts spotlight broad performance drivers across key sectors.
Top Analyst Reports for Visa, Merck & Southern Company
Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
The pharmaceutical giant's post-Keytruda plans continue to take shape.
The Northeast Science & Technology Center Advances Next Phase of Campus Enhancements
The creation and renovation of over 75,000 SF of amenity and common space to support an ecosystem of research and innovation for current and future tenants KENILWORTH, N.J. , Nov. 20, 2025 /PRNewswire...
Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's
Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and the...
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in ...
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in a...
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Merck (MRK) Gains EU Approval for Subcutaneous Keytruda
Merck (MRK) Gains EU Approval for Subcutaneous Keytruda
Merck gets EU nod for subcutaneous version of Keytruda
Merck's Keytruda wins EU approval for a new injectable form, offering greater treatment options for adults. Read more here.
Merck's (MRK) HIV Treatment Matches Gilead's in Key Trial
Merck's (MRK) HIV Treatment Matches Gilead's in Key Trial
Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial
Merck (MRK) Shares Positive Phase 3 Trial Results for HIV Treatment
Merck (MRK) Shares Positive Phase 3 Trial Results for HIV Treatment
Merck (MRK) Gains EU Approval for New Keytruda Administration
Merck (MRK) Gains EU Approval for New Keytruda Administration
Merck's oral HIV treatment meets main goal in late-stage study
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial.
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the...
European Commission Approves Subcutaneous Administration of KEYTRUDA (pembrolizumab) for All Adult Indications Approved in the European Union
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administrat...
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous ...
Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.